The litigation came in response to Teva’s abbreviated new drug application seeking approval for a generic version of Xtampza ER, Collegium’s extended-release formulation of oxycodone, before Collegium’s applicable patents expired, the report said.
The settlement grants Teva a license to market its generic version of Xtampza ER in the U.S. starting Sept. 2, 2033, the report said. Teva agreed to a consent judgment confirming its generic products infringe upon Collegium’s patents and those patents are valid and enforceable. Further details weren’t immediately available.
“As a company committed to being the leader in responsible pain management, we seek to deliver scientific innovation through differentiated products for people suffering from pain. We are pleased with the outcome of the ANDA settlement with Teva because it highlights the value of that innovation in the context of the Xtampza ER franchise,” Shirley Kuhlmann, executive vice president and general counsel of Collegium, said in the report.
Read the full report here.
More articles on surgery centers:
7 charged in $41 million healthcare fraud scheme in Alabama
14 lawsuits, settlements in anesthesiology this year
DOJ charges 345 defendants responsible for $6B+ in false claims
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.